KRON Kronos Bio Inc
772
$1.01
$0.02
(1.94%)
| Watchers | 772 |
| 52-Wk Low | $0.731 |
| 52-Wk High | $2.29 |
| Market Cap | $61.9M |
| Volume | 499,831.00 |
| 52-Wk High | $2.29 |
| 52-Wk Low | $0.731 |
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsGlobe Newswire • about 2 months ago
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half...
Share to Feed
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for...
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Kronos Bio (KRON Research Report), with a price target...
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today...
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Company eliminates three executive officer roles and appoints new Executive Leadership teamSAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq...
Kronos Bio, Inc. (NASDAQ:KRON Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,430,000 shares, a...